Related Experiment Video

Updated: Aug 16, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Toward the development of new medicinal leads with selectivity for protein kinase C isozymes

Kazuhiro Irie1, Yu Nakagawa, Hajime Ohigashi

  • 1Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan. irie@kais.kyoto-u.ac.jp

Chemical Record (New York, N.Y.)
|July 26, 2005
PubMed

Insights

Researchers developed a synthetic peptide library to create selective protein kinase C (PKC) modulators. Indolactam-V was identified as a lead compound, showing that substituent position on the indole ring is key for selective PKC isozyme and C1 domain binding.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Protein Kinase C (PKC) isozymes are crucial in various biological processes and are implicated in tumor promotion.
  • Phorbol esters, common tumor promoters, activate PKC isozymes by binding to their C1A and/or C1B domains.
  • Selective targeting of individual PKC isozymes is therapeutically important due to their diverse roles.

Purpose of the Study:

  • To develop agents with selective binding to individual PKC C1 domains.
  • To identify novel compounds that can modulate specific PKC isozyme activity.
  • To understand the structure-activity relationships governing C1 domain-ligand interactions.

Main Methods:

  • Creation of a synthetic C1 peptide library encompassing all PKC isozymes.
  • Screening of the library to identify lead compounds with selective binding.
  • Structure-activity relationship studies on identified lead compounds, including indolactam-V.
  • Computational analysis to understand binding interactions, such as CH/pi interactions.

Main Results:

  • Identification of indolactam-V as a promising lead compound from the C1 peptide library.
  • Demonstration that the hydrophobic substituent position on the indole ring dictates PKC isozyme and C1 domain selectivity.
  • Elucidation of potential CH/pi interactions between indolactam-V and Pro-11 of the PKCdelta C1B domain.
  • Synthesis of naphtholactam-V8 as an example of structural optimization.

Conclusions:

  • The synthetic C1 peptide library is a valuable tool for discovering selective PKC modulators.
  • Indolactam-V and its derivatives represent a promising class of compounds for targeting specific PKC isozymes.
  • Understanding the molecular interactions at the C1 domain is critical for designing potent and selective therapeutic agents.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...